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Summary: Postherpetic neuralgia (PHN) is a chronic and 
painful condition that may occur after a herpes zoster infection. 
The frequency of PHN after untreated zoster varies widely. Age 
is the most important risk factor for development of PHN. The 
condition occurs in an estimated 50% of patients older than 50 
years. The pain of PHN can be severe and debilitating and is 
frequently associated with allodynia. Although in most patients 
pain remits within the first year, it may persist for a lifetime. 
Tricyclic antidepressants (TCAs), topical agents, opioids, and 
gabapentin, a structural y-amino butyric acid (GABA) ana- 
logue, are the only agents that have demonstrated efficacy in 
randomized clinical trials for treatment of both the shooting and 
the burning form of pain associated with PHN. TCAs are 
among the most commonly used classes of agents for treating 
PHN and are effective in a significant proportion of patients. 
However, various adverse events can limit treatment. These 
side effects tend to be more acute in the elderly, the population 
most likely to suffer from PHN. Topical agents have led to mild 
to moderate improvement in patients with PHN but are usually 
ineffective as monotherapy for this condition. Until recently, 
carbamazepine was the only antiepileptic drug evaluated for the 
treatment of PHN. Over the past few years, however, gaba- 
pentin has received increasing attention as a useful treatment 
for neuropathic pain. Gabapentin lacks significant drug-drug 
interactions and has a favorable safety profile, which makes it 
particularly useful for treatment of PHN. Key Words: Posther- 
petic neuralgia-Gabapentin-Herpes zoster. 
HERPES ZOSTER 
Infection with the varicella zoster virus (VZV) can 
result in systemic infection or in a localized infection 
known as herpes zoster (HZ) or shingles (I) .  Herpes 
zoster, with an annual incidence close to 0.3% (2), arises 
from reactivation of a latent infection in the sensory gan- 
glia and leads to a characteristic vesicular rash in a der- 
matomal pattern. Usually pain precedes the rash by days 
to weeks (3) ,  and the most commonly affected sites in- 
clude the trigeminal ganglion (herpes zoster ophthalmi- 
cus) and the thoracic dermatomes ( 4 3 .  The rash usually 
disappears in an average of 3 weeks. Treatment with 
antivirals (acyclovir, famciclovir, or valacyclovir) re- 
duces the duration of pain in acute HZ neuralgia (6) and 
might significantly reduce the time to pain relief when 
treatment with tricyclic antidepressants (TCAs) is insti- 
tuted to treat postherpetic neuralgia (PHN) (7). Although 
treatment with steroids was not found to reduce the in- 
cidence of PHN (8,9), the value of antiviral treatment in 
this regard has not yet been settled (10-14). When added 
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to antivirals, steroid treatment did not result in additional 
benefit (12). 
POSTHERPETIC NEURALGIA 
PHN is a chronic painful condition that sometimes 
occurs after a zoster infection. Although most investiga- 
tors confirm persistent pain for at least 3 months after 
healing of the characteristic rash before making this di- 
agnosis, others have diagnosed PHN as early as 3 to 4 
weeks after healing (15-17) or not until 6 months after 
healing ( 18). The frequency of PHN after untreated zos- 
ter has varied widely in different series, but a meta- 
analysis of 14 placebo-controlled clinical trials of acy- 
clovir for acute zoster found that 22% of placebo-treated 
patients went on to develop this condition (19). The most 
important risk factor for developing PHN is age (20), 
with incidence estimates of 50% for patients older than 
50 years and 75% for those above 65 years (2,4,21). 
Women are more commonly affected than men (22) ,  
which might be a reflection of the predominance of 
women in the older age group. 
The pain of PHN can be quite severe and incapacitat- 
ing and is described as lancinating, stabbing, shooting, or 
steady and burning, and is frequently associated with 
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allodynia. Although the pain remits in most patients 
within the first year, it can persist for years or even a 
lifetime. The duration of the pain is also age-dependent, 
with pain lasting more than 1 year estimated to occur in 
22% of patients over 55 years and 48% of patients over 
70 years (2,21). 
Treatment of PHN: randomized clinical trials 
Tricyclic antidepressants 
Tricyclic antidepressants (TCAs) are among the most 
commonly used classes of drugs for treatment of PHN. 
The best response has occurred after treatment with ad- 
renergically active antidepressants such as amitriptyline 
(23-26), desipramine (27), and maprotiline (26). 
Five controlled crossover trials evaluating the efficacy 
of TCAs in the treatment of PHN have been conducted 
(23-27). Three of these trials were placebo-controlled 
(two evaluating amitriptyline and one desipramine) and 
the other two were comparative trials of amitriptyline vs. 
maprotiline in the first and amitriptyline vs. zimeldine in 
the other. A positive response was defined as one in 
which the pain relief was at least of moderate degree or 
in which the patient was not disabled by the pain at the 
maximal tolerated dose. These trials were relatively 
small, each enrolling a total of 15 to 58 patients. In the 
placebo-controlled trials, a positive response was expe- 
rienced by 47-67% of patients during the amitriptyline 
phase compared with 5 4 %  during the placebo phase. In 
the comparative trials, a positive response was experi- 
enced by 44% and 60% of patients during treatment with 
amitriptyline compared with 18% and 7% of patients 
during treatment with maprotiline and zimeldine, respec- 
tively. In general, the sooner treatment was initiated, the 
better the overall response (28). 
Although TCAs were effective in a significant propor- 
tion of patients, adverse events such as dry mouth, uri- 
nary retention, constipation, sedation, orthostatic hypo- 
tension and cardiac conduction block can be treatment 
limiting (29). These side effects tend to be most acute in 
the elderly population, the age group most likely to suffer 
from PHN. To minimize these effects, TCAs should be 
started at a low dose and titrated slowly. A starting dose 
of 10 mg at bedtime for elderly patients is recommended, 
with weekly increments of 10-25 mg. The usual daily 
effective dose is 25-150 mg given once a day at bedtime. 
The full therapeutic efficacy of TCAs might not be seen 
before 1 to 2 weeks and sometimes not before 4 to 6 
weeks (30). They should be used with caution in the 
elderly and in patients with heart disease, narrow-angle 
glaucoma, or prostatism. 
Topical agents 
The efficacy of treatment with topical agents was also 
evaluated in PHN patients. Two randomized clinical tri- 
als found capsaicin to be effective for treatment of PHN. 
After 6 weeks of treatment, capsaicin-treated patients 
experienced a 15-30% mean improvement in pain on the 
visual analogue scale compared with a 1-5% improve- 
ment for patients receiving vehicle cream (31,32). A 
third trial reported capsaicin to be ineffective in this con- 
dition (33). Recent double-blind trials have shown that 
lidocaine gel and patch administered in a single session 
resulted in significant short-term partial relief of PHN 
pain (1 7). 
Opioids 
For patients with refractory pain, opioids are occasion- 
ally used. A double-blind trial in patients with PHN 
found that pain relief after treatment with 120 mg oral 
codeine did not differ significantly from that after pla- 
cebo (35). A more recent study using a higher dose found 
that opioid treatment is effective in relieving the pain of 
PHN. In a single-center, randomized, double-blind, pla- 
cebo-controlled crossover trial design, 50 patients were 
started on oxycodone or placebo and titrated over 4 
weeks to tolerability up to a maximal daily dose of 60 mg 
(36). This was followed by crossover to the alternate 
treatment for 4 weeks with no intervening washout pe- 
riod. Other therapies for PHN were continued at un- 
changed dosages for the duration of the trial. Pain inten- 
sity and pain relief were assessed using daily diaries, 
visual analogue scales for pain intensity, and categorical 
scales for both pain intensity and pain relief. Data from 
38 patients were included in the efficacy analysis. Com- 
pared with placebo, oxycodone produced statistically 
significant pain relief and lessening of pain intensity, as 
measured on both the visual analogue and categorical 
scales. Seventy-six percent of patients reported adverse 
events on oxycodone, including constipation, sedation, 
and nausea. 
Opioid treatment is not widely accepted for treatment 
of chronic neuropathic pain, and should be reserved for 
refractory patients after other therapies have been ex- 
hausted. 
Other treatments 
Until recently, carbamazepine was the only antiepilep- 
tic drug (AED) evaluated for treatment of PHN. In the 
single randomized clinical trial, carbamazepine was 
found to be effective in treating the lancinating compo- 
nent but was ineffective against the steady and burning 
component of pain (37). 
Although treatments such as calcium channel blockers 
(38) and mexiletine (39) have been anecdotally reported 
to be effective, their efficacy was never established in 
randomized clinical trials. For refractory patients, there 
is also anecdotal evidence supporting the use of anes- 
thetic blockade and neurosurgical procedures. 
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GABAPENTIN AND THE TREATMENT OF PAIN 
Gabapentin is a structural y-amino butyric acid 
(GABA) analogue that is approved by the United States 
Food and Drug Administration as an adjunctive AED for 
seizures of partial onset in patients 12 years of age and 
older. Over the past few years, it has received increasing 
attention as a drug potentially useful for treatment of 
neuropathic pain. Anecdotal and open-label series re- 
ports have discussed its efficacy in a wide variety of 
painful conditions, including complex regional pain syn- 
dromes, trigeminal neuralgia, postherpetic neuralgia, and 
neuropathic pain of the head and neck (40-45). It was 
also found to be effective in reducing tactile allodynia, 
mechano hyperalgesia, and thermal hyperalgesia in a va- 
riety of animal models of neuropathic pain, including the 
chronic constriction injury model (46), the formalin and 
carageenan foodpad tests, the streptozotocin model, and 
a model of postoperative pain (47-50). Its mechanism of 
action in the treatment of pain is not yet well understood. 
The binding site of gabapentin, the a2-A subunit of a 
voltage-dependent calcium channel, might be mechanis- 
tically important in the drug’s antineuralgic activity, be- 
cause these calcium channels are significant in the de- 
velopment of central sensitization following deafferenta- 
tion. 
USE OF GABAPENTIN FOR TREATMENT OF 
PHN: A RANDOMIZED CLINICAL TRIAL 
The safety and efficacy of gabapentin for treatment of 
PHN were evaluated in a large multicenter, double-blind, 
placebo-controlled, parallel group, randomized, 8-week 
clinical trial (5 1). This section provides a synopsis of that 
study. 
Subjects and methods 
Subjects from 16 United States outpatient clinical cen- 
ters participated in the study (51). A 1-week baseline 
period preceded a 4-week titration phase during which 
gabapentin was titrated up to 3600 mg daily or the maxi- 
mal tolerated dose. This was followed by a 4-week fixed- 
dose period at the maximal tolerated dose (Fig. 1). Pa- 
tients randomized to receive treatment with gabapentin 
were started at an initial dose of 300 mg/day. The maxi- 
mal daily gabapentin dose was 900 mg, 1800 mg, 2400 
mg, and 3600 mg at the end of weeks 1, 2, 3, and 4, 
respectively. Eligibility criteria included age (18 years or 
older) and pain of at least moderate severity, i.e., a mini- 
mum score of 40 mm on the Visual Analogue Scale of 
the Short-Form McGill Pain Questionnaire (SF-MPQ), 
and of at least 3 months’ duration after disappearance of 
the zoster rash. Patients could be maintained on stable 
doses of a narcotic or a TCA for the duration of the trial. 
Eligible patients who gave informed consent under- 
went physical and neurologic examinations and were in- 
Screening i Double-Blind Treatment Phase 
Phase i Titration Period I Fixed-Dose Period 
. 3-12 capsuleslday 
I I I I 1 I I 
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(Randomization) (Termination) 
FIG. 1. Gabapentin for the treatment of post-herpetic neuralgia: 
a randomized controlled trial. Study design. Data from 
Rowbotham et al. (51). 
structed to complete diaries evaluating overall pain and 
sleep. A minimum of five visits was scheduled for each 
patient: initial enrollment and screening; randomization; 
and after 2, 4, and 8 weeks of study treatment. 
During the second visit (1 week after baseline), pa- 
tients completed the SF-MPQ, the Short-Form-36 
(SF-36) Quality of Life Questionnaire, and the Profile of 
Mood States (POMS). Those patients who met the in- 
clusion criteria and had completed at least four diaries 
were randomized to treatment with either gabapentin or 
placebo. Patients completed the SF-MPQ at weeks 2, 4, 
and 8, and the SF-36 and POMS at the final visit (week 
8). In addition, patients completed the Subjects’ Global 
Impression of Change Questionnaire and investigators 
completed the Clinical Global Impression of Change 
Questionnaire. 
The primary efficacy parameter was the change in 
average daily pain score from the baseline week to the 
final study week, which was assessed from daily pain 
diaries and measured on a modified 1 1 -point Likert scale 
(0 = no pain, 10 = worst possible pain) for the duration 
of the trial. Secondary efficacy parameters included 
changes from baseline in the following: average daily 
sleep rating. score; the SF-MPQ total score, along with 
subscores for affective and sensory components of pain; 
the SF-36; and the POMS. Additional secondary efficacy 
parameters were present pain intensity (PPI) scores from 
the SF-MPQ, the Clinical Global Impression of Change, 
and the Subjects’ Global Impression of Change. Mea- 
sures of drug safety included the frequency and severity 
of adverse events, 
Results 
A total of 229 patients, mostly elderly individuals (me- 
dian age 73 years), were randomized in the trial during 
the baseline visit (51). Of these patients, 184 (80.3%) 
completed the study, 15.3% discontinued the study be- 
cause of adverse events, and 4.4% discontinued for other 
reasons. There was no significant difference between the 
active treatment and the placebo groups with respect to 
the percentage of patients who completed the study. Of 
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those patients treated with gabapentin who participated 
in the fixed dosing period, 83% received at least 2400 mg 
and 65% received 3600 mg gabapentin daily. 
Primary eflicacy analysis 
The intent-to-treat analysis showed a statistically sig- 
nificant improvement in the average daily pain score in 
favor of the gabapentin-treated patients (p < 0.001) (51). 
For patients receiving gabapentin, the average daily pain 
score decreased by 33%, from a baseline value of 6.3 to 
4.2 at the end of week 8. Placebo-treated patients had an 
8% reduction in average daily pain scores, from 6.5 at 
baseline to 6.0 at week 8. These results represent a mean 
change from baseline of -2.1 (SD k 2.1) and -0.5 (SD k 
1.6) in the gabapentin and placebo groups, respectively 
(Fig. 2). The pain reduction seen in the gabapentin group 
was already established at week 2, with a further reduc- 
tion at week 4. At week 8, the reduction was maintained 
at the week 4 level. These end-of-study results were 
clinically significant. 
Secondary efJicacy anaZysis 
Patients treated with gabapentin reported significant 
improvement in average daily sleep rating scores com- 
pared with those in the placebo group (p < 0.001) (51). In 
addition, for gabapentin-treated patients, mean SF-MPQ 
scores improved markedly for sensory pain (p < O.OOl), 
affective pain (p < O.OOl), and total pain (p < 0.001). 
Improvement in the SF-MPQ ratings of PPI was also 














f 0 Placebo (n = 1 16) Gabapentin (n = 109) 
4' I 
2 4 8 
Weeks 
' p  < 0.001 
FIG. 2. Change from baseline in average daily pain score (intent- 
to-treat analysis). Asterisk indicates p < 0.001. From Rowbotham 
et al. (51). 
statistically significant for patients treated with gabapen- 
tin (p < 0.01). At the conclusion of the trial, 16% of 
gabapentin-treated patients were pain free compared 
with 8 %VO of patients treated wikh p\acebo. 
The Subjects' Global Impression of Change Question- 
naire revealed that gabapentin provided a notable mea- 
sure of pain relief for a large percentage of patients. A 
total of 43% of gabapentin-treated patients rated their 
pain as moderately or much improved at the end of the 
trial compared with baseline (categorical scale) vs. 126 
of placebo-treated patients. The majority of patients in 
the placebo group (60%) reported no change in their 
level of pain compared with 23% of the gabapentin- 
treated subjects. The investigators' assessment was simi- 
lar, as indicated by the Clinical Global Impression of 
Change Questionnaire. 
The SF-36, which assessed physical functioning, role- 
physical, bodily pain, vitality, and mental health, all 
showed gabapentin to be superior to placebo (p 50.01). 
In addition, patients treated with gabapentin showed sig- 
nificantly greater improvement in the POMS assessment 
of depression-dejection, anger-hostility, fatigue-inertia, 
confusion-bewilderment and total mood disturbance (p 
50.01) (51). 
Safety and tolerability 
The frequency, nature, and severity of adverse events 
were assessed in 229 patients, 113 of whom received 
GBP and 116 placebo (5  1). In this trial, gabapentin was 
well tolerated, with 13.3% of patients exiting because of 
side effects considered to be related to the study medi- 
cation vs. 9.5% of placebo-treated patients. 
There were no reports of serious adverse events de- 
termined by the investigator to be related to gabapentin 
treatment. Adverse events that occurred at a higher rate 
in the gabapentin group than in the placebo group were 
somnolence (27% vs. 5%) ,  dizziness (24% vs. 5%), 
ataxia (7% vs. O%), peripheral edema (10% vs. 3%), and 
infection (8% vs. 3%). The most frequent adverse event 
in the placebo group was pain, which occurred in 10.3% 
of patients compared with 4.4% in the gabapentin group. 
In conclusion, the results of this study demonstrate 
that gabapentin is effective for reducing PHN pain, has a 
positive effect on sleep, quality of life, and mood, and is 
well tolerated. 
As with TCAs, a low starting dose and a titration 
schedule will minimize the side effects that may occur 
with gabapentin treatment. A starting dose of 100 mg at 
bedtime is recommended for elderly patients. If toler- 
ated, the dose can be increased to 300 mg at bedtime 2 or 
3 days later, followed by 300 mg increments every 3-5 
days until the patient experiences adequate pain relief. 
The usual effective daily dose ranges from 900 to 3600 
mg administered tid. 
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SUMMARY 
TCAs, topical agents, opioids, and gabapentin are the 
only drugs that have demonstrated efficacy for treatment 
of PHN in randomized clinical trials. In general, it is 
agreed that treatment with topical agents leads to mild or 
moderate improvement at best and is not effective as the 
sole therapy for this condition. TCAs have shown effec- 
tiveness in a large proportion of patients. However, an- 
ticholinergic and other adverse effects can limit toler- 
ability. Conversely, lack of drug-drug interactions and 
an excellent safety profile make gabapentin very attrac- 
tive for treatment of PHN. The results of an 8-week study 
confirm the efficacy of gabapentin in reducing PHN pain 
and demonstrate its beneficial effects on sleep, overall 
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